Ainos Reports Third Quarter 2026 Results and Highlights Expanding AI Nose Commercial Momentum
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ainos (AIMD) reported third-quarter 2026 revenue of $642,889, alongside a narrower net loss and additional AI Nose semiconductor orders. Revenue compared with $2,167 a year earlier, while GAAP net loss narrowed to $1,886,074 from $2,931,702. Gross margin rose to 83.4% from 78.0%. Results included a one-time $600,000 VELDONA license fee.
After quarter-end, Ainos signed a $9 million agreement for 5,000 additional AI Nose systems, with $4.5 million due within 60 days of signing and the balance upon completion and delivery. It also collected $950,000 in contractual payments. Ainos expects its initial $2.1 million AI Nose agreement to generate approximately $175,000 quarterly over the three-year service period beginning Q4 2026. At September 30, cash was $660,916 against $16,594,900 in current liabilities, including $11,000,000 in convertible notes. Discussions have begun to address convertible notes due in 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointFollow-on AI Nose purchase agreement totals $9 million for 5,000 additional systems with an existing customer. 84% of market cap
- Moderate pointQ3 2026 revenue rose to $642,889 from $2,167 a year earlier.
- Moderate pointQ3 GAAP net loss narrowed to $1,886,074 from $2,931,702 a year earlier.
- Moderate pointQ3 GAAP gross margin increased to 83.4% from 78.0% a year earlier.
- Moderate pointQ3 operating expenses declined to $2,220,938 from $2,785,883 a year earlier.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Initial $2.1 million agreement: Ainos expects approximately $175,000 quarterly over three years beginning Q4 2026. 20% of market cap
- Moderate pointPost-quarter contractual collections totaled $950,000 from VELDONA licensing and AI Nose commercialization. 8.9% of market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.VELDONA framework offers potential $10 million licensing opportunities, with partner-funded assigned clinical and regulatory development.
9 minor points
- Minor pointAI Nose deliveries reached 1,400 systems under the initial backend semiconductor customer agreement.
- Minor pointFront-end semiconductor customer placed initial orders for AI Nose.
- Minor pointVELDONA technology transfer triggered a $600,000 initial license fee, recognized in Q3 and collected after quarter-end.
- Minor point. Forward-looking: it has not happened yet and may not happen.VELDONA terms retain core platform ownership and participation in applicable net sublicensing revenue for Ainos.
- Minor pointAI Nose technologies and robotic integration secured three Japanese patents.
- Minor pointNine-month 2026 revenue increased to $643,202 from $113,037 a year earlier.
- Minor pointNine-month GAAP net loss narrowed to $8,940,605 from $10,302,714 a year earlier.
- Minor pointNine-month operating expenses fell to $8,903,168 from $9,786,141 a year earlier.
- Minor pointCash increased to $660,916 at September 30, 2026, from $417,353 at December 31, 2025.
Negative
- Major pointCurrent liabilities totaled $16,594,900 against $2,069,829 in current assets at September 30, 2026.
- Major point. Forward-looking: it has not happened yet and may not happen.Convertible notes of $11,000,000 are due in 2027; discussions to address them have begun.
- Moderate pointOutstanding common shares increased to 7,554,324 at September 30, 2026, from 5,822,675 at December 31, 2025.
- Moderate pointStockholders' equity declined to $1,721,037 at September 30, 2026, from $7,562,582 at December 31, 2025.
- Minor pointLoan payable reached $2,812,940 at September 30, 2026, versus none at December 31, 2025.
5 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.Follow-on order requires completion and delivery of all equipment before the balance after the initial $4.5 million is payable.
- Minor pointVELDONA framework includes conditional additional licensing opportunities; the potential $10 million is not fully secured.
- Minor pointQ3 revenue included a one-time $600,000 VELDONA initial license fee.
- Minor pointQ3 interest expense rose to $204,763 from $176,584 a year earlier.
- Minor pointNine-month interest expense rose to $581,801 from $534,986 a year earlier.
News Explained
Ainos describes VELDONA as a potential
Details
Market move: AIMD +7.31% vs previous close. 3Q26 earnings report
On Nov 16, the day this news came out, the latest delayed price for AIMD is 7.31% above the previous close. Our momentum scanner has recorded 89 alerts for this stock so far that day. The latest delayed price is $1.32. Relative volume is exceptionally heavy at 17921.4x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Revenue
- $642,889; up 29,567% year over year
- Q3 2026
- GAAP net loss
- $(1,886,074); improved 36% year over year
- Q3 2026
- Non-GAAP adjusted net loss
- $(672,352); improved 51% year over year
- Q3 2026
- GAAP gross margin
- 83.4%, versus 78.0%
- Q3 2026 versus Q3 2025
- Non-GAAP gross margin
- 83.6%, versus 78.0%
- Q3 2026 versus Q3 2025
- Follow-on AI Nose order
- $9 million; 5,000 additional systems
- Signed after quarter-end with the existing backend semiconductor customer
- Initial payment
- $4.5 million within 60 days of signing
- Follow-on AI Nose agreement
- Expected recurring revenue
- Approximately $175,000 per quarter
- Beginning Q4 2026 over the three-year service period
Previous Earnings,AI Reports
-
Revenue fell to $152 and quarterly net loss widened to $4.59 million year over year.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
gaap financial
non-gaap financial
convertible-notes financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, TX / ACCESS Newswire / November 16, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced financial results for the third quarter ended September 30, 2026, highlighting increased revenue, a narrower net loss and progress in AI Nose semiconductor commercialization and VELDONA licensing. Subsequent to quarter-end, the Company secured an additional
Eddy Tsai, Chairman, President and Chief Executive Officer, commented:
"Our third-quarter results show progress in translating commercial agreements into revenue. Revenue reached
"Following quarter-end, our existing backend semiconductor customer signed a
"Our focus is on fulfilling customer commitments, expanding recurring services and directing operating resources toward Chemical Intelligence commercialization. Our chemical dataset grew from more than 1 billion records in September to over 3 billion in October, supporting product refinement and broader applications. Our potential
Christopher Lee, Chief Financial Officer of Ainos, added:
"Our Q3 2026 results demonstrate progress in both revenue generation and operating discipline. GAAP net loss improved
"Beginning in Q4 2026, we expect the
"Following quarter-end, we collected
Q3 2026 Highlights
- Delivered 1,400 AI Nose systems to backend semiconductor customer under the
$2.1 million , three-year subscription services; expecting$175,000 revenues per quarter beginning Q4 2026 over the service period. - Received initial orders from a front-end semiconductor customer.
- Introduced second-generation AI Nose, with software and hardware upgrades designed for continuous sensing in industrial environment.
- Surpassed 1 billion real-world chemical records, strengthening the data foundation for model development and application-specific validation.
- Secured three Japanese patents covering AI Nose technologies and their integration with robotic systems.
- Established a potential
$10 million VELDONA licensing framework for two initial indications and conditional additional licensing opportunities. The partner funds assigned clinical and regulatory development; Ainos retains core platform ownership and participation in applicable net sublicensing revenue. - Completed VELDONA technology transfer, triggering the
$600,000 initial license fee recognized in Q3 and collected after quarter-end. - Launched Atmosphere Engine, a modular platform designed to generate nitrogen and oxygen from ambient air near the point of use for semiconductor and AI infrastructure applications.
- Improved financial performance: Q3 2026 revenue rose 29,
567% year over year to$642,889 ; GAAP gross margin expanded to83.4% from78.0% . GAAP net losses improved36% year over year.
Q4 2026 Developments
- Signed a
$9 million purchase agreement for 5,000 additional AI Nose systems with the existing backend semiconductor customer. A$4.5 million initial payment is due within 60 days of signing, with the balance payable upon completion and delivery of all equipment. - Collected
$950,000 in contractual payments, from VELDONA licensing and AI Nose semiconductor commercialization. - Surpassed 3 billion real-world chemical data points, announced October 30, more than tripling September's milestone and expanding resources for product and application development.
Non-GAAP Financial Measures
In addition to results determined in accordance with U.S. GAAP, this press release includes Adjusted Net Loss, a non-GAAP financial measure. Management defines Adjusted Net Loss as net loss, the most directly comparable GAAP measure, adjusted to exclude share-based compensation, depreciation and amortization, and common stock issued as a special stock bonus. Adjusted Net Loss does not exclude interest or income taxes and is not a measure of EBITDA.
Management uses Adjusted Net Loss to evaluate trends in cash operating costs. Ainos believes it helps investors assess the cash resources needed to fund its operations. However, share-based compensation is a recurring cost, and Adjusted Net Loss does not reflect equity dilution, cash interest on Ainos's debt, or capital expenditures. Other companies may calculate similar measures differently. Adjusted Net Loss should not be considered in isolation or as a substitute for net loss or other GAAP measures. A reconciliation of net loss to Adjusted Net Loss for the three and nine months ended September 30, 2026 and 2025 is provided in the tables below.
About Ainos, Inc.
Ainos, Inc. (NASDAQ:AIMD) is building Chemical Intelligence for Physical AI, giving machines a new way to understand the physical world by turning chemical signals in the air into digital information. Its AI Nose technology enables intelligent systems to sense and interpret changes in their surroundings, while Atmosphere Engine extends that intelligence toward environmental control. Together, they form a sensing-to-control architecture designed to help machines sense, understand, and ultimately optimize their environments across semiconductor manufacturing, robotics, industrial systems, healthcare environments, and other real-world applications where AI increasingly interacts with the physical world. Follow Ainos on X, formerly known as Twitter, @AinosInc, and LinkedIn to stay up to date. Visit Ainos' media room at https://ainos.suite.accessnewswire.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the uncertainty of the contemplated collaboration framework and the expected receipt of license fees, manufacturing license fees and other consideration thereunder; our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our licensed indications and product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Investor Relations
ir@ainos.com
Ainos, Inc.
Condensed Consolidated Balance Sheets
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| (Unaudited) | ||||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 660,916 | $ | 417,353 | ||||
Accounts receivable | 643,064 | 22 | ||||||
Inventory, net | 243,729 | 295,565 | ||||||
Other current assets | 522,120 | 425,859 | ||||||
Total current assets | 2,069,829 | 1,138,799 | ||||||
Intangible assets, net | 15,843,468 | 19,226,003 | ||||||
Property and equipment, net | 264,923 | 343,281 | ||||||
Other assets | 137,717 | 163,025 | ||||||
Total assets | $ | 18,315,937 | $ | 20,871,108 | ||||
Liabilities and Stockholders' Equity | ||||||||
Current liabilities: | ||||||||
Contract liabilities | $ | 350,000 | $ | 350,000 | ||||
Convertible notes payable | 11,000,000 | - | ||||||
Loan payable | 2,812,940 | - | ||||||
Accrued expenses and other current liabilities | 2,431,960 | 728,683 | ||||||
Total current liabilities | 16,594,900 | 1,078,683 | ||||||
Convertible notes payable - noncurrent | - | 11,000,000 | ||||||
Other long-term liabilities | - | 1,229,843 | ||||||
Total liabilities | 16,594,900 | 13,308,526 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity: | ||||||||
Preferred stock, | - | - | ||||||
Common stock, | 87,143 | 69,827 | ||||||
Common Shares to be issued are 2,801 and nil shares as of September 30, 2026 and December 31, 2025, respectively | 28 | - | ||||||
Treasury stock, at cost (1,160,000 shares held as of September 30, 2026 and December 31, 2025) | (1,972,000 | ) | (1,972,000 | ) | ||||
Additional paid-in capital | 80,309,746 | 77,234,374 | ||||||
Accumulated deficit | (76,460,933 | ) | (67,520,328 | ) | ||||
Accumulated other comprehensive loss | (242,947 | ) | (249,291 | ) | ||||
Total stockholders' equity | 1,721,037 | 7,562,582 | ||||||
Total liabilities and stockholders' equity | $ | 18,315,937 | $ | 20,871,108 | ||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
Ainos, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
Revenues | $ | 642,889 | $ | 2,167 | $ | 643,202 | $ | 113,037 | ||||||||
Cost of revenues | (106,623 | ) | (477 | ) | (107,439 | ) | (19,647 | ) | ||||||||
Gross profit | 536,266 | 1,690 | 535,763 | 93,390 | ||||||||||||
Operating expenses: | ||||||||||||||||
Research and development (including amounts of related party of | 1,696,019 | 1,990,630 | 5,236,288 | 5,626,514 | ||||||||||||
Selling, general and administrative | 524,919 | 795,253 | 3,666,880 | 4,159,627 | ||||||||||||
Total operating expenses | 2,220,938 | 2,785,883 | 8,903,168 | 9,786,141 | ||||||||||||
Loss from operations | (1,684,672 | ) | (2,784,193 | ) | (8,367,405 | ) | (9,692,751 | ) | ||||||||
Non-operating (expenses) income, net: | ||||||||||||||||
Interest expense | (204,763 | ) | (176,584 | ) | (581,801 | ) | (534,986 | ) | ||||||||
Other income, net | 3,361 | 29,075 | 8,601 | (74,977 | ) | |||||||||||
Total non-operating expenses, net | (201,402 | ) | (147,509 | ) | (573,200 | ) | (609,963 | ) | ||||||||
Net loss before income taxes | (1,886,074 | ) | (2,931,702 | ) | (8,940,605 | ) | (10,302,714 | ) | ||||||||
Provision for income taxes | - | - | - | - | ||||||||||||
Net loss | $ | (1,886,074 | ) | $ | (2,931,702 | ) | $ | (8,940,605 | ) | $ | (10,302,714 | ) | ||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
Results of Operations reconciliation of GAAP to Non-GAAP Measures
| The three months ended September 30, | The nine months ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
GAAP net loss attributable to stockholders | $ | (1,886,074 | ) | $ | (2,931,702 | ) | $ | (8,940,605 | ) | $ | (10,302,714 | ) | ||||
Adjustments: | ||||||||||||||||
Stock-based compensation expense | 21,305 | 348,356 | 2,033,926 | 1,728,055 | ||||||||||||
Stock issued for special stock bonus | - | - | - | 862,230 | ||||||||||||
Depreciation and Amortization | 1,192,417 | 1,206,641 | 3,553,809 | 3,578,083 | ||||||||||||
Non-GAAP net loss attributable to stockholders | $ | (672,352 | ) | $ | (1,376,705 | ) | $ | (3,352,870 | ) | $ | (4,134,346 | ) | ||||
SOURCE: Ainos, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Ainos AIMD's third-quarter 2026 financial results?
Ainos reported $642,889 in revenue and a $1,886,074 GAAP net loss for the quarter ended September 30, 2026. A year earlier, revenue was $2,167 and GAAP net loss was $2,931,702. GAAP gross margin increased to 83.4% from 78.0%.
How large is Ainos's follow-on AI Nose order and when are payments due?
The follow-on agreement covers 5,000 additional AI Nose systems for $9 million with the existing backend semiconductor customer. An initial $4.5 million payment is due within 60 days of signing, with the balance payable upon completion and delivery of all equipment.
What development responsibilities and rights does Ainos retain under the VELDONA licensing framework?
The partner funds assigned clinical and regulatory development, while Ainos retains core platform ownership and participation in applicable net sublicensing revenue. The potential $10 million framework covers two initial indications and conditional additional licensing opportunities.